EZH2 and neoplasm: Growth curves of responsive tumors demonstrate that EZH2 inhibition had no effect on tumor growth alone during the pretreatment phase, but that tumors immediately began to regress once HDACi was included in the regimen, and continued to shrink over time (Fig 1H and S1 Data).